KRRO Logo

Korro Bio, Inc. (KRRO) Stock Forecast & Price Prediction

Live KRRO Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$32.23

-2.39 (-6.90%)

12 Month Price Forecast For KRRO

$32.23
Current Price
$324.33M
Market Cap
8 Ratings
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to KRRO Price Forecasts

+458.5%
To High Target of $180.00
+339.0%
To Median Target of $141.50
+225.8%
To Low Target of $105.00

KRRO Price Momentum

-17.5%
1 Week Change
-8.6%
1 Month Change
-41.4%
1 Year Change
-15.3%
Year-to-Date Change
-67.1%
From 52W High of $98.00
+7.4%
From 52W Low of $30.00

๐Ÿค” Considering Korro Bio (KRRO)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 10:00 AM UTC

KRRO Analyst Ratings & Price Targets

Based on our analysis of 8 Wall Street analysts, KRRO has a bullish consensus with a median price target of $141.50 (ranging from $105.00 to $180.00). Currently trading at $32.23, the median forecast implies a 339.0% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 458.5% upside. Conversely, the most conservative target is provided by Luca Issi at RBC Capital, suggesting a 225.8% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

KRRO Analyst Consensus

8
Buy
0
Hold
0
Sell

KRRO Price Target Range

Low
$105.00
Average
$141.50
High
$180.00
Current: $32.23

Latest KRRO Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for KRRO.

Date Firm Analyst Rating Change Price Target
Nov 22, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $115.00
Nov 18, 2024 Jones Trading Catherine Novack Buy Initiates $130.00
Nov 13, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $115.00
Oct 21, 2024 RBC Capital Luca Issi Outperform Maintains $105.00
Oct 21, 2024 Raymond James Steven Seedhouse Strong Buy Initiates $153.00
Oct 18, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Maintains $115.00
Sep 19, 2024 RBC Capital Luca Issi Outperform Reiterates $95.00
Sep 17, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $100.00
Aug 14, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $100.00
Aug 14, 2024 RBC Capital Luca Issi Outperform Maintains $95.00
Aug 14, 2024 William Blair Myles Minter Outperform Initiates $0.00
May 21, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $100.00
May 15, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Maintains $100.00
May 15, 2024 BMO Capital Kostas Biliouris Outperform Maintains $120.00
Mar 28, 2024 HC Wainwright& Co. Buy Maintains $0.00
Mar 28, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Maintains $115.00
Mar 27, 2024 Piper Sandler Yasmeen Rahimi Overweight Maintains $180.00
Mar 27, 2024 RBC Capital Luca Issi Outperform Maintains $90.00
Mar 26, 2024 BMO Capital Kostas Biliouris Outperform Reiterates $120.00
Mar 12, 2024 RBC Capital Luca Issi Outperform Reiterates $70.00

Stocks Similar to Korro Bio, Inc.

The following stocks are similar to Korro Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Korro Bio, Inc. (KRRO) Financial Data

Korro Bio, Inc. has a market capitalization of $324.33M with a P/E ratio of -0.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -74.5%.

Valuation Metrics

Market Cap $324.33M
Enterprise Value $227.39M
P/E Ratio -0.6x
PEG Ratio -3.4x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +45.6%
Current Ratio 11.2x
Debt/Equity 23.3x
ROE -74.5%
ROA -35.3%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Korro Bio, Inc. logo

Korro Bio, Inc. (KRRO) Company Overview

About Korro Bio, Inc.

What They Do

Develops RNA editing genetic medicines for diseases.

Business Model

Korro Bio, Inc. operates as a biopharmaceutical company focused on the discovery, development, and commercialization of genetic medicines utilizing its RNA editing platform, OPERA. The company generates revenue through product development, collaborations, and potential sales of its therapies targeting rare and prevalent diseases.

Additional Information

Founded in 2018 and based in Cambridge, Massachusetts, Korro Bio's lead product candidate, KRRO-110, is in preclinical trials for Alpha-1 Antitrypsin Deficiency. The company is also working on treatments for Parkinson's disease, ALS, and severe alcohol-associated hepatitis, and has a collaboration with Novo Nordisk for cardiometabolic disease therapies.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

101

CEO

Mr. Ram Aiyar MBA, Ph.D.

Country

United States

IPO Year

2019

Korro Bio, Inc. (KRRO) Latest News & Analysis

KRRO stock latest news image
Quick Summary

The REWRITE study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of KRRO-110 through single and multiple escalating dose evaluations.

Why It Matters

The REWRITE study's evaluation of KRRO-110 could indicate its potential market viability, impacting stock prices and investment decisions in biotech sectors.

Source: GlobeNewsWire
Market Sentiment: Neutral
KRRO stock latest news image
Quick Summary

Korro Bio, Inc. (Nasdaq: KRRO) will participate in upcoming investor conferences, focusing on their RNA editing genetic medicines for various diseases.

Why It Matters

Korro Bio's participation in investor conferences signals active engagement with the investment community, potentially impacting stock visibility and investor sentiment.

Source: GlobeNewsWire
Market Sentiment: Neutral
KRRO stock latest news image
Quick Summary

Korro Bio, Inc. will present at the Jefferies London Healthcare Conference on November 19, 2024. Key executives, including the CEO and CFO, will participate in the event.

Why It Matters

Korro Bio's presentation at a major healthcare conference highlights its focus on innovative RNA editing therapies, which could attract investor interest and influence stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
KRRO stock latest news image
Quick Summary

A regulatory filing for a Phase 1/2 clinical study on Alpha-1 Antitrypsin Deficiency has been submitted to the Australian Bellberry HREC.

Why It Matters

The filing for the clinical study indicates progress in drug development for AATD, potentially impacting future revenues and market position for the involved biotech company.

Source: GlobeNewsWire
Market Sentiment: Neutral
KRRO stock latest news image
Quick Summary

Korro Bio shares rose while Wave Life Sciences shares fell after an analyst recommended Korro as a superior investment in the RNA-editing sector.

Why It Matters

Diverging stock performances highlight market sentiment on RNA-editing investments, signaling potential shifts in valuation and focus towards Korro Bio over Wave Life Sciences.

Source: Investors Business Daily
Market Sentiment: Negative
KRRO stock latest news image
Quick Summary

Korro Bio, Inc. (KRRO) has a consensus price target suggesting a 239.5% upside. Upward earnings estimate revisions may indicate potential near-term stock growth.

Why It Matters

A 239.5% upside potential suggests significant growth opportunities for Korro Bio, Inc. (KRRO). Upward earnings estimate revisions may indicate positive market sentiment and potential stock gains.

Source: Zacks Investment Research
Market Sentiment: Positive

Frequently Asked Questions About KRRO Stock

What is Korro Bio, Inc.'s (KRRO) stock forecast for 2025?

Based on our analysis of 8 Wall Street analysts, Korro Bio, Inc. (KRRO) has a median price target of $141.50. The highest price target is $180.00 and the lowest is $105.00.

Is KRRO stock a good investment in 2025?

According to current analyst ratings, KRRO has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $32.23. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for KRRO stock?

Wall Street analysts predict KRRO stock could reach $141.50 in the next 12 months. This represents a 339.0% increase from the current price of $32.23. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Korro Bio, Inc.'s business model?

Korro Bio, Inc. operates as a biopharmaceutical company focused on the discovery, development, and commercialization of genetic medicines utilizing its RNA editing platform, OPERA. The company generates revenue through product development, collaborations, and potential sales of its therapies targeting rare and prevalent diseases.

What is the highest forecasted price for KRRO Korro Bio, Inc.?

The highest price target for KRRO is $180.00 from Yasmeen Rahimi at Piper Sandler, which represents a 458.5% increase from the current price of $32.23.

What is the lowest forecasted price for KRRO Korro Bio, Inc.?

The lowest price target for KRRO is $105.00 from Luca Issi at RBC Capital, which represents a 225.8% increase from the current price of $32.23.

What is the overall KRRO consensus from analysts for Korro Bio, Inc.?

The overall analyst consensus for KRRO is bullish. Out of 8 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $141.50.

How accurate are KRRO stock price projections?

Stock price projections, including those for Korro Bio, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.